Your SlideShare is downloading. ×
Immunisation against serogroup B meningococcal disease - hopes and fears
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Immunisation against serogroup B meningococcal disease - hopes and fears

748
views

Published on

Panel discussion moderated by Prof Paul Heath at Meningitis Research Foundation's 2013 Conference, Meningitis and Septicaemia in Children and Adults …

Panel discussion moderated by Prof Paul Heath at Meningitis Research Foundation's 2013 Conference, Meningitis and Septicaemia in Children and Adults
Panellists: Prof Adam Finn, University of Bristol, Dr Simon Nadel, Prof Robert Read, Dr Matthew Snape and Dr Caroline Trotter

Published in: Health & Medicine, Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
748
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Immunisation against serogroup B meningococcal disease – hopes and fears
  • 2. Immunisation against serogroup B meningococcal disease – hopes and fears 1. "Policies that block access to vaccines or vaccine development purely on the basis of economic considerations are ethically flawed"
  • 3. Immunisation against serogroup B meningococcal disease – hopes and fears 2. "Should economic considerations around vaccines be different to those for other healthcare interventions, different for meningitis vs other infections or different for children vs adults"
  • 4. Immunisation against serogroup B meningococcal disease – hopes and fears 3. "Is the recent JCVI (interim) statement relevant to other MenB vaccines in development? How should vaccine manufacturers now approach the development of new vaccines, in general?"
  • 5. Immunisation against serogroup B meningococcal disease – hopes and fears 4. "is the concern started by the JCVI regarding fever/safety and its possible impact on acceptance of BEXSERO and on acceptance of routine immunisations justified? How should this be managed?
  • 6. Immunisation against serogroup B meningococcal disease – hopes and fears 5. "the JCVI states that a population based evaluation of BEXSERO is required - do you agree? how would you do it? what should its endpoints be? who should fund this?"
  • 7. Immunisation against serogroup B meningococcal disease – hopes and fears 25 October 2013 JCVI: Update on the outcome of consultation about use of BEXSERO meningococcal B vaccine in the UK “…submissions received included references to new and recently published evidence and further analyses are necessary to respond fully……..interim position statement cannot be updated until these analyses are complete.”